Free Trial

BioAtla (BCAB) Competitors

BioAtla logo
$0.83 +0.03 (+3.88%)
Closing price 03:58 PM Eastern
Extended Trading
$0.84 +0.01 (+1.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCAB vs. ACTU, CCCC, PYXS, CTOR, THTX, ACOG, NVCT, NKTX, MOLN, and GLSI

Should you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Actuate Therapeutics (ACTU), C4 Therapeutics (CCCC), Pyxis Oncology (PYXS), Citius Oncology (CTOR), Theratechnologies (THTX), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Nkarta (NKTX), Molecular Partners (MOLN), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry.

BioAtla vs. Its Competitors

BioAtla (NASDAQ:BCAB) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

77.2% of BioAtla shares are held by institutional investors. 11.2% of BioAtla shares are held by insiders. Comparatively, 69.3% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioAtla has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Actuate Therapeutics has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500.

Actuate Therapeutics has a consensus target price of $20.33, suggesting a potential upside of 161.52%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Actuate Therapeutics is more favorable than BioAtla.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
Actuate Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, BioAtla had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for BioAtla and 1 mentions for Actuate Therapeutics. BioAtla's average media sentiment score of 0.95 beat Actuate Therapeutics' score of 0.83 indicating that BioAtla is being referred to more favorably in the media.

Company Overall Sentiment
BioAtla Positive
Actuate Therapeutics Positive

Actuate Therapeutics has lower revenue, but higher earnings than BioAtla.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtla$11M4.44-$69.78M-$1.10-0.76
Actuate TherapeuticsN/AN/A-$27.28MN/AN/A

Actuate Therapeutics' return on equity of 0.00% beat BioAtla's return on equity.

Company Net Margins Return on Equity Return on Assets
BioAtlaN/A -1,177.18% -137.51%
Actuate Therapeutics N/A N/A -281.83%

Summary

BioAtla and Actuate Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCAB vs. The Competition

MetricBioAtlaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$48.86M$3.39B$6.04B$10.49B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-0.7622.9085.1927.32
Price / Sales4.44269.18516.16194.55
Price / CashN/A46.9537.5761.53
Price / Book3.3310.5312.426.81
Net Income-$69.78M-$52.58M$3.32B$276.59M
7 Day Performance-8.92%1.06%0.80%0.15%
1 Month Performance19.73%16.05%10.52%8.17%
1 Year Performance-57.33%18.41%76.14%35.50%

BioAtla Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCAB
BioAtla
0.5961 of 5 stars
$0.83
+3.9%
N/A-60.2%$48.86M$11M-0.7660Analyst Forecast
ACTU
Actuate Therapeutics
1.9165 of 5 stars
$7.02
+0.6%
$20.33
+189.6%
+2.0%$162.24MN/A0.0010
CCCC
C4 Therapeutics
3.7672 of 5 stars
$2.28
+0.4%
$8.50
+272.8%
-65.6%$161.56M$35.58M-1.44150
PYXS
Pyxis Oncology
2.0756 of 5 stars
$2.47
-3.9%
$7.75
+213.8%
+1.3%$159.39M$16.15M-1.5460News Coverage
Analyst Upgrade
CTOR
Citius Oncology
3.045 of 5 stars
$1.87
-1.1%
$6.00
+220.9%
+61.9%$157.84MN/A0.00N/AGap Up
THTX
Theratechnologies
N/A$3.42
+0.9%
N/A+174.3%$157.21M$84.38M-17.99140High Trading Volume
ACOG
Alpha Cognition
2.9572 of 5 stars
$7.40
-1.1%
$20.00
+170.3%
N/A$156.35MN/A-4.63N/A
NVCT
Nuvectis Pharma
3.2504 of 5 stars
$6.05
+0.7%
$15.33
+153.4%
-6.5%$152.87MN/A-5.178
NKTX
Nkarta
2.3955 of 5 stars
$2.15
+0.9%
$13.60
+532.6%
-39.3%$151.28MN/A-1.45140High Trading Volume
MOLN
Molecular Partners
1.4971 of 5 stars
$3.72
+0.3%
$8.00
+115.0%
-26.7%$149.79M$5.65M-1.79180News Coverage
Analyst Forecast
GLSI
Greenwich LifeSciences
1.2458 of 5 stars
$11.28
+3.4%
$42.00
+272.3%
-23.7%$148.71MN/A-8.293Analyst Forecast

Related Companies and Tools


This page (NASDAQ:BCAB) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners